[go: up one dir, main page]

WO2009105192A3 - Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax - Google Patents

Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax Download PDF

Info

Publication number
WO2009105192A3
WO2009105192A3 PCT/US2009/000995 US2009000995W WO2009105192A3 WO 2009105192 A3 WO2009105192 A3 WO 2009105192A3 US 2009000995 W US2009000995 W US 2009000995W WO 2009105192 A3 WO2009105192 A3 WO 2009105192A3
Authority
WO
WIPO (PCT)
Prior art keywords
saccharides
glycoprotein
reactive
cross
vaccine against
Prior art date
Application number
PCT/US2009/000995
Other languages
French (fr)
Other versions
WO2009105192A2 (en
Inventor
Joanna Kubler-Kielb
Evguenii Vinogradov
Rachel Schneerson
Haijing Hu
Stephen H. Leppla
John B. Robbins
Original Assignee
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services
National Research Council Of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Research Council Of Canada filed Critical The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services
Priority to US12/918,281 priority Critical patent/US20100330074A1/en
Publication of WO2009105192A2 publication Critical patent/WO2009105192A2/en
Publication of WO2009105192A3 publication Critical patent/WO2009105192A3/en
Priority to US13/909,992 priority patent/US8926986B2/en
Priority to US14/563,920 priority patent/US20150093412A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provide are immunogen c compositions and methods or el c t ng an immune response against B. anthracis and other bacteria that contain 3-methyl-3- hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides. Conjugates of 3- methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.
PCT/US2009/000995 2008-02-19 2009-02-17 Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax WO2009105192A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/918,281 US20100330074A1 (en) 2008-02-19 2009-02-17 Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax
US13/909,992 US8926986B2 (en) 2008-02-19 2013-06-04 Use of saccharides cross-reactive with Bacillus anthracis spore glycoprotein as a vaccine against anthrax
US14/563,920 US20150093412A1 (en) 2008-02-19 2014-12-08 Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6650908P 2008-02-19 2008-02-19
US61/066,509 2008-02-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/918,281 A-371-Of-International US20100330074A1 (en) 2008-02-19 2009-02-17 Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax
US13/909,992 Division US8926986B2 (en) 2008-02-19 2013-06-04 Use of saccharides cross-reactive with Bacillus anthracis spore glycoprotein as a vaccine against anthrax

Publications (2)

Publication Number Publication Date
WO2009105192A2 WO2009105192A2 (en) 2009-08-27
WO2009105192A3 true WO2009105192A3 (en) 2009-11-05

Family

ID=40578048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/000995 WO2009105192A2 (en) 2008-02-19 2009-02-17 Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax

Country Status (2)

Country Link
US (3) US20100330074A1 (en)
WO (1) WO2009105192A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088288A2 (en) * 2010-01-15 2011-07-21 University Of Georgia Research Foundation, Inc. Hybridoma cell lines and monoclonal antibodies recognizing anthrose saccharide of bacillus anthracis
TWI461214B (en) * 2011-06-13 2014-11-21 Univ Chang Gung Biodegradable water-sensitive glue, a drug delivery system as a carrier thereof, and a pharmaceutical composition for the treatment and / or prevention of eye diseases
WO2015152908A1 (en) * 2014-04-02 2015-10-08 U.S. Army Medical Research Institute Of Infectious Diseases Rapid dual direct fluorescent antibody assay for the identification of bacillus anthracis
CN103954750B (en) * 2014-04-03 2015-09-30 广东省生态环境与土壤研究所 A kind of method of immunomagnetic beads and fast detection Oneida Shewanella

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050118194A1 (en) * 2003-12-01 2005-06-02 Sin Yoke M. Oral vaccine, method for its preparation and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050118194A1 (en) * 2003-12-01 2005-06-02 Sin Yoke M. Oral vaccine, method for its preparation and use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KUBLER-KIELB JOANNA ET AL: "Saccharides cross-reactive with Bacillus anthracis spore glycoprotein as an anthrax vaccine component", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 105, no. 25, June 2008 (2008-06-01), pages 8709 - 8712, XP002542414, ISSN: 0027-8424 *
MEHTA ALOK S ET AL: "Synthesis and antigenic analysis of the BclA glycoprotein oligosaccharide from the Bacillus anthracis exosporium", CHEMISTRY - A EUROPEAN JOURNAL, WILEY - V C H VERLAG GMBH & CO. KGAA, WEINHEIM, DE, vol. 12, no. 36, 13 December 2006 (2006-12-13), pages 9136 - 9149, XP002487161, ISSN: 0947-6539 *
TAKEUCHI KASUMI ET AL: "Flagellin Glycans from two pathovars of Pseudomonas syringae contain rhamnose in D and L configurations in different ratios and modified 4-amino-4,6-dideoxyglucose", JOURNAL OF BACTERIOLOGY, vol. 189, no. 19, October 2007 (2007-10-01), pages 6945 - 6956, XP002542413, ISSN: 0021-9193 *
VINOGRADOV E ET AL: "The structure of the capsular polysaccharide of Shewanella oneidensis strain MR-4", CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 340, no. 10, 25 July 2005 (2005-07-25), pages 1750 - 1753, XP004944007, ISSN: 0008-6215 *

Also Published As

Publication number Publication date
US20150093412A1 (en) 2015-04-02
WO2009105192A2 (en) 2009-08-27
US20130273097A1 (en) 2013-10-17
US20100330074A1 (en) 2010-12-30
US8926986B2 (en) 2015-01-06

Similar Documents

Publication Publication Date Title
WO2009128950A8 (en) Deletion mutants of flagellin and methods of use
TW200806316A (en) Yeast-based vaccine for inducing an immune response
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
IN2012DN02736A (en)
MX2010001054A (en) Antigen-adjuvant compositions and methods.
MX2010012999A (en) Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof.
AU2010273708A8 (en) Vaccines and compositions against Streptococcus pneumoniae
WO2011027222A3 (en) Immunogenic compositions including tlr activity modulators
MX2009001412A (en) Protein matrix vaccines and methods of making and administering such vaccines.
WO2010019262A3 (en) Polyvalent vaccine
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
AU2010203451A8 (en) Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
PH12013500453B1 (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
MX2009008928A (en) Compositions comprising polysaccharide conjugates and their use as vaccines.
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
MY163871A (en) Vaccines and compositions against streptococcus pneumoniae
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
WO2009092113A3 (en) Methods and compositions for the delivery of vaccines to disrupted epithelium
MX2011007456A (en) Cna_b domain antigens in vaccines against gram positive bacteria.
WO2013022808A3 (en) Immunogenic protein conjugates and methods for making and using the same
WO2010053610A3 (en) Stable anthrax vaccine formulations
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
WO2009101475A3 (en) Use of glycosylceramides for enhancing the immune response to antigens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09712602

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12918281

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09712602

Country of ref document: EP

Kind code of ref document: A2